APA (7th ed.) Citation

CH, K., H, L., YC, O., HC, F., CC, T., & CH, W. (2026). Immune-related adverse events and neutrophil-to-lymphocyte ratio as prognostic indicators in gynecologic cancer patients receiving pembrolizumab: A real-world analysis. Frontiers in immunology, 16, 1739447. https://doi.org/10.3389/fimmu.2025.1739447

Chicago Style (17th ed.) Citation

CH, Kao, Lin H, Ou YC, Fu HC, Tsai CC, and Wu CH. "Immune-related Adverse Events and Neutrophil-to-lymphocyte Ratio as Prognostic Indicators in Gynecologic Cancer Patients Receiving Pembrolizumab: A Real-world Analysis." Frontiers in Immunology 16 (2026): 1739447. https://doi.org/10.3389/fimmu.2025.1739447.

MLA (9th ed.) Citation

CH, Kao, et al. "Immune-related Adverse Events and Neutrophil-to-lymphocyte Ratio as Prognostic Indicators in Gynecologic Cancer Patients Receiving Pembrolizumab: A Real-world Analysis." Frontiers in Immunology, vol. 16, 2026, p. 1739447, https://doi.org/10.3389/fimmu.2025.1739447.